Therefore, whether or not GATA3 mutant breast cancers have better clinical outcomes than ER+ GATA3 wild type tumors, it remains possible that mutant Gata3 or its downstream effectors could be rational targets for breast cancer therapy. This evidence concerns the gene GATA3 and breast cancer.